Grifols | GRFS - Operating Profit


Grifols reported EUR320.55M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Arca Biopharma USD -36.43M 2M Mar/2026
aTyr Pharma USD -104K 24K Jun/2026
Bio Path USD -297K 191K Mar/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cara Therapeutics USD -7.05M 1.11M Mar/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Grifols EUR 320.55M 91.01M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
TherapeuticsMD USD -1.18M 40K Jun/2024